Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Cardiovascular Diseases

Atherosclerotic Cardiovascular Disease (ASCVD) ...

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality worldwide, encompassing conditions such as coronary artery disease and stroke. The growing occurrence of...

Jan 29, 2024

MedTech News for AngioDynamics, Enhatch, AbSolutions
FDA Breakthrough Device Designation to Pi-Cardia’s ShortCut; AbSolutions Med’s REBUILD Bioabsorbable Abdominal Wall Closure Device; AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter; Enhatch Announces FDA Clearance for a TKA Patient-Specific Instrumentation System

Pi-Cardia Receives FDA Breakthrough Device Designation for ShortCut™ Pi-Cardia Ltd., a prominent player in advancing catheter-based leaflet modification solutions for heart valve treatment, revealed that its ShortCut™ device has attained Breakthrough Device Designation from the US Food and Drug Administration. S...

Find More
Pharma News for AskBio, Merck, SELLAS, RemeGen
Bayer’s AskBio Initiates Phase II GenePHIT Trial; FDA Approves Merck’s KEYTRUDA Plus Chemoradiotherapy as Treatment for Stage III-IVA Cervical Cancer; FDA Fast Track Designation to SELLAS Life Sciences R/R AML; RemeGen’s RC88; Shorla Oncology Announces FDA Filing Acceptance of New Drug Application for Novel Formulation to Treat Breast and Ovarian Cancer; Tonix Pharma’s TNX-102 SL for Fibromyalgia

Bayer’s AskBio initiates Phase II GenePHIT trial in Congestive Heart Failure Merck, also recognized as MSD in regions beyond the United States and Canada, has officially announced that the FDA has approved for the use of KEYTRUDA, Merck's anti-PD-1 therapy, in conjunction with chemoradiotherapy (CRT) for treatin...

Find More
MedTech News for Medtronic, Cala, Medline, Rivermark Medical
Medtronic Announced World’s First Approval for MiniMed 780G System; CE Mark for Medtronic’s Next Generation Micra Leadless Pacing Systems; Biosense Webster Received Approval for VARIPULSE PFA Platform; Rivermark Medical Updated on Flostent System; Cala Disclosed TAPS Therapy Data for Essential Tremor; Medline Introduced Transparent Wound Dressing

Medtronic Received CE Mark for its Next Generation Micra Leadless Pacing Systems On January 5, 2024, Medtronic announced that the Micra AV2 and Micra VR2, the next generation of its industry-leading tiny, leadless pacemakers, earned the CE (Conformité Européenne) Mark. The world's tiniest pacemakers, the rMic...

Find More

More Views & Analysis

Pharma News for Merck, AbbVie, Abbisko
Merck to Acquire Harpoon Therapeutics; Novo Nordisk Enters Into Collaborations with Omega Therapeutics and Cellarity; AbbVie’s Lutikizumab’s Phase II Trial Result for Hidradenitis Suppurativa; Abbisko’s CSF-1R Inhibitor Pimicotinib (ABSK021); Cabaletta Bio’s CABA-201; FDA Grants Fast Track” Designation for Soligenix’s Dusquetide

Lutikizumab Showed Positive Results in a Phase II Trial of Adults with Moderate to Severe Hidradenitis Suppurativa as Program Advances to Phase III AbbVie has reported the results of Phase II trials indicating that adults experiencing moderate to severe hidradenitis suppurativa, and who had previously not respon...

Find More

MedTech News for Integra, B. Braun, Medtronic, Perfuze
Integra to Buy J&J’s Acclarent; B. Braun Launches the CARESITE Micro Luer Access Devic; FDA Approves Medtronic’s Novel PulseSelect Pulsed Field Ablation System; FDA Clearances to Perfuze’s Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment; ShiraTronics Successfully Implants First Migraine System; Sight Sciences Announced the Six-Month Results For Heat Therapy Device

Integra LifeSciences to Buy Johnson & Johnson’s Acclarent and its ENT Tech On December 13, 2023, Integra LifeSciences entered into a definitive agreement to acquire Acclarent from Johnson & Johnson MedTech. Acclarent strengthens Integra's position in the ENT treatment market. Acclarent is a component of ...

Find More

Cardiac Rhythm Management Devices Market Analysis
Understanding the Growth and the Evolving Market Dynamics of Cardiac Rhythm Management Devices

Globally, cardiovascular diseases (CVDs) stand as the primary cause of mortality, claiming an estimated 17.9 million lives in 2019 alone, which accounted for 32% of all global deaths. Among these fatalities, a staggering 85% were attributed to heart attacks and strokes. Within the spectrum of noncommunicable diseas...

Find More

MedTech News for Laminar, BD, Vivos, Zilia, Penumbra
Johnson & Johnson Medtech Acquired Laminar; BD Launched Advanced Vascular Access Ultrasound System; FDA Cleared Oral Device for Severe Sleep Apnea; FDA Clearanced the Zilia OcularTM FC Retinal Camera; First Patient Enrolled in Penumbra Study of Computer-assisted Vacuum Thrombectomy; US FDA Granted the BiVACOR Total Artificial Heart IDE Approval for First-in-Human Early Feasibility Study

FDA Cleared Oral Device for Severe Sleep Apnea From Vivos Therapeutics On November 29, 2023, Vivos Therapeutics announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Vivos’s removable CARE (Complete Airway Repositioning and Expansion) oral appliances developed for treat...

Find More

Implantable Drug Delivery Devices Market Outlook
Assessing the Emerging Trends in the Evolving Implantable Drug Delivery Device Landscape

The Implantable Drug Delivery Device market has experienced a monumental surge driven by an amalgamation of technological innovation, burgeoning demand, and the strategic maneuvers of key industry players. According to DelveInsight's latest assessment, the global Implantable Drug Delivery Device Market is poised to...

Find More

MedTech News for Ethicon, Medtronic, Surmodics, GSK
Ethicon’s ETHIZIA Hemostatic Sealing Patch; FDA Approves Medtronic’s Minimally Invasive Device to Treat Hypertension; Boston Scientific Acquires Relievant Medsystems; AstraZeneca Launched Evinova; Surmodics Announced Data of the SWING Trial; GSK Advancing the Low Carbon Ventolin Program to Phase III Trials

Ethicon Announced European Approval and Introduction of ETHIZIA™ Hemostatic Sealing Patch Used to Stop Disruptive Bleeding On November 15, 2023, Ethicon, a Johnson & Johnson MedTech company, received approval for ETHIZIA™, an adjunctive hemostat solution that has been clinically proven to achieve sustained h...

Find More

Schizophrenia is a severe mental illness that interferes with a person's ability to think clearly, m.....

Find More

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction o.....

Find More

Wearable technology has been gaining momentum for the last few years as an effect of the fourth indu.....

Find More

Intra-Tumoral Cancer Therapy refers to any therapy that is delivered in very close anatomical proxim.....

Find More

Alzheimer's disease is an irreversible, progressive disorder of the brain that progressively destroy.....

Find More

Affecting the entire body, Adult Onset Still's disease (AOSD) is a rare type of inflammatory arthrit.....

Find More